急性呼吸窘迫综合征亚表型与辛伐他汀差异反应:随机对照试验二次分析
该研究为HARP-2随机对照试验的二次分析,纳入英国和爱尔兰40家ICU的539例ARDS患者,采用潜在类别分析识别出低炎症型(65%)和高炎症型(35%)两个亚表型。高炎症型患者无呼吸机天数更少、28天死亡率更高,且该亚表型中辛伐他汀组28天生存率显著高于安慰剂组。
要点
- ARDS可分低炎症型和高炎症型两个亚表型,临床与生物学特征不同。
- 高炎症型患者无呼吸机天数更少、器官衰竭自由天数更少、28天死亡率更高。
- 高炎症型患者接受辛伐他汀治疗28天生存率显著高于安慰剂组。
核心结论
- HARP-2队列中识别出两个ARDS亚表型,临床和生物学特征及结局不同。
- 高炎症型亚表型患者接受辛伐他汀相比安慰剂生存改善。
研究设计与样本
- HARP-2为多中心随机对照试验,在英国和爱尔兰40家医院ICU纳入ARDS发病48小时内患者,辛伐他汀80 mg对比安慰剂。
- 本分析对539例患者基线数据行潜在类别分析识别亚表型,比较亚表型间及治疗组间临床结局。
主要发现
- 两类别模型优于单类别模型(p<0·0001),低炎症型353例(65%),高炎症型186例(35%)。
- 高炎症型比低炎症型无呼吸机天数更少(中位2天[IQR 0-17] vs 18[IQR 0-23];p<0·0001)。
- 高炎症型比低炎症型非肺器官衰竭自由天数更少(15[0-25] vs 27[21-28];p<0·0001)。
- 高炎症型比低炎症型28天死亡率更高(73例[39%] vs 59例[17%];p<0·0001)。
- 高炎症型中辛伐他汀组28天生存率显著高于安慰剂组(p=0·008),90天生存率呈相似模式。
关键数值与推荐
- HARP-2主要结局为无呼吸机天数,次要结局包括非肺器官衰竭自由天数和死亡率。
- 高炎症型亚表型中辛伐他汀对比安慰剂28天生存率差异显著(p=0·008)。
临床怎么用
- 对ARDS患者可考虑识别高炎症型亚表型,该亚表型可能从辛伐他汀治疗中获益。
- 研究结果支持在重症临床试验中采用预测性富集策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Precision medicine approaches that target patients on the basis of disease subtype have transformed treatment approaches to cancer, asthma, and other heterogeneous syndromes. Two distinct subphenotypes of acute respiratory distress syndrome (ARDS) have been identified in three US-based clinical trials, and these subphenotypes respond differently to positive end-expiratory pressure and fluid management. We aimed to investigate whether these subphenotypes exist in non-US patient populations and respond differently to pharmacotherapies. METHODS: HARP-2 was a multicentre, randomised controlled trial of simvastatin (80 mg) versus placebo done in general intensive care units (ICUs) at 40 hospitals in the UK and Ireland within 48 h of onset of ARDS. The primary outcome was ventilator-free days, and secondary outcomes included non-pulmonary organ failure-free days and mortality. In a secondary analysis of HARP-2, we applied latent class analysis to baseline data without consideration of outcomes to identify subphenotypes, and we compared clinical outcomes across subphenotypes and treatment groups. FINDINGS: 540 patients were recruited to HARP-2. One patient withdrew consent for the use of their data, so data from 539 patients were analysed. In our secondary analysis, a two-class (two subphenotype) model was an improvement over a one-class model (p<0·0001), with 353 (65%) patients in the hypoinflammatory subphenotype group and 186 (35%) in the hyperinflammatory subphenotype group. Additional classes did not improve model fit. Clinical and biological characteristics of the two subphenotypes were similar to previous studies. Patients with the hyperinflammatory subphenotype had fewer ventilator-free days (median 2 days [IQR 0-17] vs 18 [IQR 0-23]; p<0·0001), fewer non-pulmonary organ failure-free days (15 [0-25] vs 27 [21-28]; p<0·0001), and higher 28-day mortality (73 [39%] vs 59 [17%]; p<0·0001) than did those with the hypoinflammatory subphenotype. Although HARP-2 found no difference in 28-day survival between placebo and simvastatin, significantly different survival was identified across patients stratified by treatment and subphenotype (p<0·0001). Specifically, within the hyperinflammatory subphenotype, patients treated with simvastatin had significantly higher 28-day survival than did those given placebo (p=0·008). A similar pattern was observed for 90-day survival. INTERPRETATION: Two subphenotypes of ARDS were identified in the HARP-2 cohort, with distinct clinical and biological features and disparate clinical outcomes. The hyperinflammatory subphenotype had improved survival with simvastatin compared with placebo. These findings support further pursuit of predictive enrichment strategies in critical care clinical trials. FUNDING: UK Efficacy and Mechanism Evaluation Programme and National Institutes of Health.
引用
- Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018. PMID: 30078618. doi:10.1016/S2213-2600(18)30177-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。